SciELO - Scientific Electronic Library Online

 
vol.43 issue6Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up programEconomic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma author indexsubject indexarticles search
Home Pagealphabetic serial listing  

My SciELO

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Farm Hosp. vol.43 n.6 Toledo Nov./Dec. 2019  Epub June 29, 2020

https://dx.doi.org/10.7399/fh.11215 

Originals

Nationwide current situation of hospital pharmacists in intensive care units

Marta Valera-Rubio1  , Esther Domingo-Chiva2  , Irene Aquerreta-González3  , Leonor Periáñez-Párraga4  , Jesús Ruiz-Ramos5  , Dolors Soy-Muner6  , FarMIC Work group (Pharmacists of Intensive Care and critically ill patients)

1Pharmacy Service, Virgen de la Victoria University Hospital, Málaga. Spain.

2Pharmacy Service, Integrated Care Management of Albacete. Spain.

3Pharmacy Service, University Hospital of Navarra, Pamplona. Spain.

4Pharmacy Service, Son Espases University Hospital, Palma de Mallorca. Spain.

5Pharmacy Service, La Fe University Hospital, Valencia. Spain.

6Pharmacy Service, Clínic Hospital, Barcelona. Spain.

Abstract

Objective

To describe the current situation of the hospital pharmacist in intensive care units and their activity in care, in teaching and in research.

Method

Multicenter and prospective study through a survey disseminated by the Spanish Society of Hospital Pharmacy, which consisted of several sections: personal and hospital's data, hospital's characteristics, pharmacist's involvement in intensive care units and teaching.

Results

A number of 58 completed surveys were obtained. The number of pharmacists involved in intensive care units was 1 in 77.6% of cases, assisting an average of 30.8 beds (5-70). Experience of pharmacists in the intensive care unit was 5 years on average (2 months-25 years). Visitor's pass assistance and shift changes were between “never” by 36.2% to “daily” by 22.4%. Out of respondents, 93.1% reported a part-time intensive care unit involvement. Regarding activities undertaken, between 40-60% of pharmacists manage narcotics, teaching at intensive care unit, conciliation and safety. Between 60-80%, pharmacists cover clinical nutrition, notarization, optimization of pharmacokinetics and antibiotics; and 84.5% perform pharmacotherapy follow-up. Out of the surveyed pharmacists, 77.6% have specialized medical training, rotating intensive care unit residents in 86% of cases.

Conclusions

Most of the surveyed hospitals have one part-time pharmacist in these units. In order to improve the quality of pharmaceutical care of critically ill patients, it would be necessary to extend the involvement in time and staff, regarding the current situation, and a greater number of hospitals should include pharmacists in hospital intensive care units.

KEYWORDS: Hospital pharmacist; Critical care; Intensive care unit

Introduction

Pharmacists are essential members of the multidisciplinary healthcare team, and it has been shown to significantly contribute to optimizing pharmacotherapy and prevention of medication errors1. The intensive care unit (ICU) is one of the areas that benefit most from the incorporation of a pharmacist into the care team due to the characteristics of critically ill patients, who have a severe disease, multiple organ failure and multiple comorbidities, requiring a complex pharmacotherapeutic treatment. The use of high-risk medications and the susceptibility of patients makes medication errors have more serious consequences than in other hospitalization floors2. In 2000, a work group of the Society of Critical Care Medicine and the American College of Clinical Pharmacy defined the level of clinical practice and specialized skills that should characterize the ICU pharmacist as a clinician, educator, researcher and manager, and established fundamental desirable and optimal requirements, both in pharmacy services and staff for providing pharmaceutical care to critically ill patients3. Similarly, the National Institute for Health and Care Excellence (NICE) established the optimization of pharmacotherapeutic treatments as an essential component of patient care, comprising various facets of pharmacy practice, such as medication reconciliation, treatment review, monitoring security and development of support systems for clinical decision-making5.

In a study conducted in 2015 which included 279 ICUs in the UK, it was observed that 96.6% of them had at least one pharmacist in the staffing of health care personnel. In addition, it was found in said study that pharmacists spent 24.5% of their working hours in multidisciplinary visitor's passes; 58.5% to the independent review of patients and treatments, while the remaining 17% spent their working hours in other activities related to the intensive care field5. In studies available to date, it is shown that the involvement of pharmacists in ICUs is relevant due to the fact that it has been proven to have a positive impact, both clinically and economically. The findings show that pharmaceutical interventions in connection with optimizing treatments are linked to a significant improvement in patient care, as well as to a reduction in length of ICU stay, in the incidence of adverse events and mortality6 7 8 9 10 11-12. Since 2000, in Spain, pharmacists have gradually joined different hospital's clinical areas. Nevertheless, integration in ICUs had been limited to some specific hospitals. Over the past five years, the number of pharmacists who have joined ICUs has increased, which is why in 2018 the FarMIC work group (Pharmacists of Intensive Care and critically ill patients) was established within the Spanish Society of Hospital Pharmacy (SEFH). The main objective of this group is to bring together pharmacists who -through their work experience in ICU- could share knowledge with other colleagues, encouraging activity in care, in teaching and in research of this field. During the making of the group, the need to obtain a map of the current situation regarding the pharmacist's role at the hospital in ICUs in Spain was raised, in order for it to serve as a starting point for the group's activity.

The main objective of this study is to describe the current situation of the pharmacist's role at the hospital in ICUs, their activity in care, in teaching and in research.

Methods

Multicenter, prospective study, initiated and conducted by survey by SEFH's FarMIC work group through Google®'s virtual platform forms, directed to SEFH's mailing list along with a letter explaining the reason for the survey and brief instructions on how to properly carry it out. The survey was conducted in April, 2018 and its completion was absolutely voluntary and without monetary compensation.

The questionnaire consisted of a series of semi-structured or closed questions, clearly and concisely formulated, and easy to answer. It consisted of several parts or sections, including: personal and hospital data -where respondents are pharmacists-, ICU's number and characteristics of hospital, pharmacist's involvement in ICU -taking into account the number of pharmacists, specific tasks performed, time spent and experience time for its evaluation-, training for internal resident pharmacists (FIR in Spanish) -rotations, interns, external rotating pharmacists-, and research activities carried out along with the ICU's multidisciplinary team. The details of the survey are presented in Annex I.

The obtained responses were collected in an Excel® database created for this purpose, whose access was restricted only to the researchers of the study. Each formulated question was globally and separately analyzed.

A descriptive analysis of the responses presenting qualitative variables as percentages and quantitative variables as mean (± standard deviation) was performed, in case they were distributed according to normal law, or as mean and interquartile range if not met.

Results

A number of 58 completed surveys belonging to 56 hospitals were obtained. Geographical distribution is shown in Figure 1.

Figure 1. Geographical distribution of surveys received. 

Data from the completed surveys were from hospitals with different number of beds as shown in Figure 2.

Figure 2. Characteristics of the type of hospital. 

Based on the findings, the referenced type of ICU characteristics are distributed according to Table 1.

Table 1. Characteristics of the type of intensive care unit 

ICU: intensive care unit.

As for the number of involved pharmacists activity in ICU was 1 in 77.6% of cases, 2 in 15.5% and 3 in 6.9%; processing an average of 30.8 beds for every pharmacist (5-70). Pharmacists' professional experience in clinical pharmacy activities in intensive care ranged from 2 months to 25 years, which serves a mean of 5 years.

Visitor's pass assistance and shift changes are shown in Table 2.

Table 2. Pharmacist's assistance to visitor's pass and/or shift changes 

Out of the respondents, 93.1% reported a part-time involvement at the ICU, which serves an average of 2.7 ± 1.7 daily hours. 8.6% of respondents count on interns' collaboration in ICU to carry out the activity.

The activities performed by pharmacists for pharmaceutical care in critically ill patients are shown in Table 3. In summary, less than 40% is dedicated to research and/or innovation; between 40 and 60% manages narcotics, as well as teaching ICU's personnel, also conciliation and safety; 60 to 80% covers clinical nutrition, notarization, Antimicrobial Stewardship Programs (ASP) and pharmacokinetics; and 84.5% of respondents perform validation and pharmacotherapy follow-up.

Table 3. Activities carried out by respondents on pharmaceutical care in critically ill patients 

ASP: Antimicrobial Stewardship Programs; ISO: International Organization for Standardization; ICU: intensive care unit.

Out of the respondents, 77.6% of hospitals count on FIR training, rotating residents in ICU in 86% of cases. Out of the respondents, 46.6% in external rotation for residents from other centers are accepted.

Discussion

According to the findings of our survey, the presence and activity of the hospital pharmacist in ICUs is unevenly distributed among hospitals in our area. The pharmacist's presence -if ever- in these units and its number varies widely between different hospitals in the same region. These differences are even greater when compared between regions.

Pharmacists have established themselves as team members of critically ill patients' units for over 40 years13,14. Among the multiple tasks to be performed by pharmacists in assisting critically ill patients15, include validating the global pharmacotherapeutic profile, increasing adherence to clinical guidelines, carrying out activities to optimize antimicrobial therapy, assuring treatment conciliation at admission and discharge, adjusting medication dose to various clinical processes, evaluating and monitoring nutrition, and getting involved in different multidisciplinary work committees within the hospital. However, according to the results obtained, distribution and relevance of the diverse pharmacists' tasks in said units in Spain differ from the classification presented by the American College of Clinical Pharmacy and the Society of Critical Care Medicine in its position paper regarding the essential, desirable and optimal tasks that should be included within the pharmacist's role in critical care units3. To date, the degree of implementation of pharmacists in the ICUs in Spain has been unknown. The results of this study have shown that most hospitals have a one part-time pharmacist, being temporarily supplemented with a fellow or a resident, which results in executing a large number of clinical tasks with clearly insufficient resources. Note that in the hospitals of our environment, optimizing the use of antimicrobials, teaching FIR activities of clinical nutrition and pharmacokinetic monitoring are the most frequently implemented by the respondent pharmacists -validating the pharmacological treatment being the most frequent-. The pharmacotherapy review and adaptation of critically ill patients carried out by pharmacists can reduce the stay and save costs according to multiple studies9,16. On the other hand, the management of narcotics and participation in the unit's research/innovation are activities with a lesser degree of implementation.

Notably, involvement in patient safety activities was less than 50%. Given the high risk of medication errors in this group of complex patients and their potential consequences17 18-19, setting the goal of increasing the involvement of pharmacists in the development of strategies aimed at assuring the patient's safety is certainly a pending task in our hospitals. The afore mentioned experiences on pharmacists' participation in activities aimed at different ICUs' safety have proven their ability to reduce medication errors8,20,21. In fact, various safety guidelines for the critically ill patient recommend a pharmacist's involvement in these activities as a desirable action22,23.

Limitations of our study include the methodology of sending data for its voluntary reply via e-mail. It is known that those centers with greater activity tend to participate more actively in surveys than others. Thus, the activity of pharmacists in the ICUs in Spain could be less than it is shown in our findings. However, the homogeneous distribution of surveyed hospitals both in size and complexity allow collecting a wide variety of centers in terms of resources and available time, which properly ascertains the type of activities performed on critically ill patients in our environment.

In short, the pharmacist's participation in critical care units is irregular in Spanish hospitals. In order to improve the quality of pharmaceutical care for critically ill patients, it is essential to extend the involvement in time and staff regarding the current situation, as well as having more centers include pharmacists in the multidisciplinary teams for ICU patients.

Annex I:

SURVEY for HP MAP in ICU

References

Khalili H, Karimzadeh I, Mirzabeigi P, Dashti-Khavidaki S. Evaluation of clinical pharmacist's interventions in an infectious diseases ward and impact on patient's direct medication cost. Eur J Intern Med. 2013;24:227-33. DOI: 10.1016/j.ejim.2012.11.014 [ Links ]

Lisha J, Annalakshmi V, Maria J, Padmini D. Adverse Drug Reactions in Critical Care Setting: A Systematic Review. Curr Drug Saf. 2017;12(3):147-61. DOI: 10.2174/1574886312666170710192409 [ Links ]

Rudis MI, Brandl KM. Position paper on critical care pharmacy services. Society of Critical Care Medicine and American College of Clinical Pharmacy Task Force on Critical Care Pharmacy Services. Crit Care Med. 2000;28:3746-50. DOI: 10.1097/00003246-200011000-00037 [ Links ]

Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes (Internet). Manchester: National Institute for Health and Care Excellence; 2015 (consultado 23/10/2017). Disponible en: https://www.nice.org.uk/guidance/ng5Links ]

Borthwick M, Barton G, Bourne RS, McKenzie C. Critical care pharmacy workforce: UK deployment and characteristics in 2015. Int J Pharm Pract. 2018;26:325-33. DOI: 10.1111/ijpp.12408 [ Links ]

Jiang SP, Xu YY, Ping-Yang B, Wu WF, Zhang XG, Lu XY, et al. Improving antimicrobial dosing in critically ill patients receiving continuous venovenous hemofiltration and the effect of pharmacist dosing adjustment. Eur J Intern Med. 2014;25:930-5. DOI: 10.1016/j.ejim.2014.08.001 [ Links ]

Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64:2483-7. DOI: 10.2146/ajhp060674 [ Links ]

Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282:267-70. DOI: 10.1001/jama.282.3.267 [ Links ]

MacLaren R, Bond CA, Martin SJ, Fike D. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med. 2008;36:3184-9. DOI: 10.1097/CCM.0b013e31818f2269 [ Links ]

Montazeri M, Cook DJ. Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med. 1994;22:1044-8. DOI: 10.1097/00003246-199406000-00027 [ Links ]

Saokaew S, Maphanta S, Thangsomboon P. Impact of pharmacist's interventions on cost of drug therapy in intensive care unit. Pharm Pract (Granada). 2009;7:81-7. DOI: 10.4321/S1886-36552009000200003 [ Links ]

Shulman R, McKenzie CA, Landa J, Bourne RS, Jones A, Borthwick M, et al. Pharmacist's review and outcomes: Treatment-enhancing contributions tallied, evaluated, and documented (PROTECTED-UK). J Crit Care. 2015;30:808-13. DOI: 10.1016/j.jcrc.2015.04.008 [ Links ]

Horn E, Jacobi J. The critical care clinical pharmacist: evolution of an essential team member. Crit Care Med. 2006;34(3 Suppl):S46-51. [ Links ]

Erstad BL, Haas CE, O'Keeffe T, Hokula CA, Parrinello K, Theodorou AA. Interdisciplinary patient care in the intensive care unit: focus on the pharmacist. Pharmacotherapy. 2011;31:128-37. [ Links ]

Jurado LV, Steelman JD. The role of the pharmacist in the intensive care unit. Crit Care Nurs Q. 2013;36:407-14. [ Links ]

Louzon P, Jennings H, Ali M, Kraisinger M. Impact of pharmacist management of pain, agitation, and delirium in the intensive care unit through participation in multidisciplinary bundle rounds. Am J Health Syst Pharm. 2017;74:253-62. [ Links ]

Foster MJ, Gary JC, Sooryanarayana SM. Direct Observation of Medication Errors in Critical Care Setting: A Systematic Review. Crit Care Nurs Q. 2018;41:76-92. [ Links ]

Machotka O, Manak J, Kubena A, Vlcek J. Incidence of intravenous drug incompatibilities in intensive care units. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:652-6. [ Links ]

Valentin A, Capuzzo M, Guidet B, Moreno R, Metnitz B, Bauer P, et al. Errors in administration of parenteral drugs in intensive care units: multinational prospective study. BMJ. 2009;338:b814. [ Links ]

Cuesta López I, Sánchez Cuervo M, Candela Toha Á, Benedí González J, Bermejo Vicedo T. Impact of the implementation of vasoactive drug protocols on safety and efficacy in the treatment of critically ill patients. J Clin Pharm Ther. 2016;41:703-10. [ Links ]

Wang T, Benedict N, Olsen KM, Luan R, Zhu X, Zhou N, et al. Effect of critical care pharmacist's intervention on medication errors: A systematic review and metaanalysis of observational studies. J Crit Care. 2015;30:1101-6. [ Links ]

Kane-Gill SL, Dasta JF, Buckley MS, Devabhakthuni S, Liu M, Cohen H, et al. Executive Summary: Clinical Practice Guideline: Safe Medication Use in the ICU. Crit Care Med. 2017;45:1546-51. [ Links ]

Kane-Gill S, Weber RJ. Principles and practices of medication safety in the ICU. Crit Care Clin. 2006;22:273-90. [ Links ]

How to cite this paper: Valera-Rubio M, Domingo-Chiva E, Aquerreta-González I, Periáñez-Párraga L, Ruiz-Ramos J, Soy-Muner D, FarMIC Work group (Pharmacists of Intensive Care and critically ill patients). Nationwide current situation of hospital pharmacists in intensive care units. Farm Hosp. 2019;43(6):182-6.

Funding: No funding.

Contribution to the scientific literature:

The role of pharmacists in intensive care units is widely practiced across countries, being involved in different activities: optimizing the pharmacotherapy treatment and ensuring the patient's safety. It has proven an improvement in clinical and economical results. However, the hospitals' degree of involvement in the intensive care units in our environment is unknown.

Our study shows for the first time in Spain the degree of implementation of hospital pharmacists in intensive care units, showing a great diversity in the carried out activities, as well as the time spent on pharmaceutical care of critically ill patients.

Received: January 27, 2019; Accepted: July 03, 2019

Author of correspondence Marta Valera Rubio Hospital Universitario Virgen de la Victoria Campus de Teatinos s/n 29010, Málaga, Spain. Email: marta_valera@hotmail.com

Conflict of interests

No conflict of interests.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License